Filing Analysis
Rapid Micro Biosystems, Inc. filed an 8-K to announce its financial results for the second quarter ended June 30, 2026.
📋 Key Facts
- Reporting period: Second Quarter ended June 30, 2026.
- Filing date: August 7, 2026.
- The filing includes a press release (Exhibit 99.1) detailing financial results.
Rapid Micro Biosystems reported the results of its 2026 Annual Meeting of Stockholders held on May 21, 2026. Stockholders elected Richard Kollender as a Class II Director and ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor for the fiscal year ending December 31, 2026.
📋 Key Facts
- Annual Meeting held on May 21, 2026
- Richard Kollender elected as Class II Director (term ending 2029)
- PricewaterhouseCoopers LLP ratified as independent registered public accounting firm for FY2026
- 37,099,555 shares present in person or by proxy out of 41,267,511 eligible shares
Rapid Micro Biosystems, Inc. (RPID) entered into an underwriting agreement on May 18, 2026 for an underwritten public offering of shares, pre-funded warrants, and two series of common stock warrants, expected to raise approximately $8.9 million in net proceeds. Simultaneously, the Company entered into a Securities Purchase Agreement with its own directors and officers (D&Os) for a concurrent registered direct offering raising approximately $140,000 — flagging a related-party transaction. The aggregate capital raise is modest relative to the complexity of the warrant structure, and proceeds are directed entirely to working capital and general corporate purposes, suggesting ongoing cash needs.
🚩 Red Flags
- Concurrent Securities Purchase Agreement with directors and officers (D&Os) constitutes a related-party transaction — raises governance and alignment concerns.
- Net proceeds of only ~$8.9 million directed solely to working capital and general corporate purposes, signaling ongoing and significant cash burn.
- Massive potential dilution: Series A and Series B warrants issued 1:1 with all shares/pre-funded warrants, effectively tripling the potential share count from this offering alone.
- Series B Warrants include Black-Scholes value cash payout upon fundamental transactions, creating a significant liability disincentive against M&A or strategic transactions.
- Series B Warrants grant 25% participation rights in all future equity offerings for 12 months — creates persistent dilution overhang.
- Complex pre-funded warrant structure is characteristic of investors unwilling to take direct share exposure, often seen in financially stressed micro-caps.
- Combined offering price of $1.955 per share suggests stock is trading at or near multi-year lows for an emerging growth life sciences company.
- Forced exercise provision on Series A Warrants is an unusual term that may pressure holders and complicate capital structure management.
- Multiple 8-K items filed simultaneously (Items 1.01 and 9.01) covering both the public offering and the related-party D&O transaction.
📋 Key Facts
- Underwriting Agreement dated May 18, 2026 with TD Securities (USA) LLC and Lake Street Capital Markets LLC as representatives.
- Primary offering: 3,581,000 shares of Class A Common Stock plus Series A and Series B warrants; pre-funded warrants for up to 1,463,000 additional shares in lieu of common stock.
- Combined offering price: $1.955 per share (with accompanying warrants); $1.945 per pre-funded warrant unit.
- Series A Warrant exercise price: $1.955/share; exercisable 6 months from issuance; expires 1 year from issuance.
- Series B Warrant exercise price: $2.340/share; exercisable 6 months from issuance; expires 5 years from issuance.
- Estimated net proceeds from primary offering: approximately $8.9 million after underwriting discounts, commissions, and offering expenses.
- Concurrent registered direct offering to D&Os (directors and officers) via Securities Purchase Agreement: 71,607 shares plus matching Series A and Series B warrants at $1.955/share combined price, raising approximately $140,000 gross proceeds.
- All proceeds designated for working capital and general corporate purposes.
- Offering expected to close on or about May 20, 2026.
- Issued under existing shelf registration statement on Form S-3 (File No. 333-276081), declared effective December 26, 2023.
- Series B Warrants include 12-month participation rights for holders to participate in future equity issuances up to 25% of each offering.
- Series B Warrants include Black-Scholes value payout right upon fundamental transactions.
- Company classified as an emerging growth company.
- Maximum ownership caps on warrant exercise set at 4.5%, 4.99%, or 9.99% (adjustable up to 19.99% with 61 days' notice).
- Filing signed by Sean Wirtjes, Chief Financial Officer, on May 19, 2026.
Rapid Micro Biosystems, Inc. announced its financial results for the first quarter ended March 31, 2026, via a press release. The filing serves as a standard quarterly update on the company's financial condition and results of operations.
📋 Key Facts
- Announced Q1 2026 financial results on May 13, 2026.
- The results cover the fiscal period ended March 31, 2026.
- The information was furnished under Item 2.02 and is not deemed 'filed' for Section 18 liability purposes.
- Exhibit 99.1 contains the full press release detailing the financial performance.
Rapid Micro Biosystems, Inc. announced the departure of Chief Operating Officer John Wilson, effective April 10, 2026. CEO Robert Spignesi will assume the role of principal operating officer, and Mr. Wilson will provide consulting services through June 30, 2026.
📋 Key Facts
- John Wilson notified the company of his departure on March 23, 2026, citing a desire to spend more time with family.
- The departure is not the result of any disagreement with the company regarding operations, policies, or practices.
- CEO Robert Spignesi will take over the responsibilities of principal operating officer effective April 10, 2026.
- Mr. Wilson entered into a Consulting Services and Separation Agreement on March 26, 2026.
- The consulting agreement pays $200 per hour, capped at 20 hours per month, ending June 30, 2026.
- Mr. Wilson's vested stock options exercise period is extended to March 31, 2027, subject to weekly volume selling limits.
Rapid Micro Biosystems reported its Q4 and full-year 2025 financial results and announced a significant multi-system order from Samsung Biologics for its Growth Direct platform.
📋 Key Facts
- Announced financial results for the fourth quarter and fiscal year ended December 31, 2025, on March 12, 2026.
- Disclosed a new multi-system order from Samsung Biologics for the Company's Growth Direct platform.
- The filing includes Item 2.02 (Results of Operations) and Item 7.01 (Regulation FD Disclosure).
Rapid Micro Biosystems, Inc. issued a press release announcing preliminary unaudited revenue results and business highlights for the fourth quarter and full year ended December 31, 2025.
📋 Key Facts
- Report date: January 13, 2026
- Reporting period: Q4 and Full Year ended December 31, 2025
- Content: Preliminary unaudited revenue results and business highlights
- The information is furnished under Item 2.02 and not 'filed' for purposes of Section 18 liability.
Rapid Micro Biosystems, Inc. filed an 8-K to announce its financial results for the third quarter ended September 30, 2025.
📋 Key Facts
- Report date: November 7, 2025
- Reporting period: Third Quarter ended September 30, 2025
- The filing includes a press release (Exhibit 99.1) regarding financial results.
- Information under Item 2.02 is not considered 'filed' for purposes of Section 18 liability.
Rapid Micro Biosystems entered into a $45.0 million Loan and Security Agreement (LSA) with multiple tranches, having already drawn down an initial $20.0 million First Tranche on August 8, 2025. The agreement includes significant warrants for equity issuance and carries high interest rates and prepayment penalties.
🚩 Red Flags
- High interest rate (initial 11.5%) and floating rate structure.
- Significant prepayment penalties: up to 3.0% in year one, plus a 4.0% 'End of Term Payment'.
- Warrant issuance (equity kicker) associated with debt drawdowns, which may lead to future dilution.
- LSA includes a default event triggered by the delisting of the company's securities from Nasdaq.
📋 Key Facts
- Entered into a Loan and Security Agreement (LSA) with Lenders and Trinity Capital Inc. as agent.
- Total facility amount: up to $45.0 million across four tranches.
- First Tranche of $20.0 million was drawn down on August 8, 2025.
- Remaining tranches ($10M, $10M, and $5M) are subject to commercial/operational milestones or lender discretion.
- Interest rate: Floating rate, initially set at 11.5% per annum (floor of 11.0%).
- First Tranche drawdown included the issuance of warrants for up to 179,104 shares at $3.35/share.
- Warrants are issued at a price equal to the lower of the 10-day VWAP or the prior day's closing price.
- Maturity date is September 1, 2030; includes an 'End of Term Payment' of 4.0% of drawn amounts.
Rapid Micro Biosystems, Inc. announced via an 8-K that CEO Robert Spignesi has issued a letter regarding a recently diagnosed medical condition. While not a formal resignation, the disclosure of a serious health issue for a key executive in a micro-cap company introduces significant leadership uncertainty.
🚩 Red Flags
- Key Person Risk: The health of the President and CEO is critical to company operations and investor confidence.
- Uncertainty regarding succession planning or temporary leadership changes.
📋 Key Facts
- Date of report: June 17, 2025
- CEO Robert Spignesi issued a letter regarding a recently diagnosed medical condition
- The filing includes the CEO's letter as Exhibit 99.1
Rapid Micro Biosystems, Inc. announced the resignation of Class II Director Jeffrey Schwartz and the results of its annual meeting of stockholders held on May 22, 2025.
🚩 Red Flags
- None identified. The resignation of a director was explicitly stated to not be due to any disagreement regarding operations, policies, or practices.
📋 Key Facts
- Jeffrey Schwartz resigned from the Board of Directors and all committees, effective May 22, 2025.
- Mr. Schwartz served as Class II director and Chair of the Nominating and Corporate Governance Committee since April 2018.
- The company held its annual meeting on May 22, 2025, with 34,921,524 shares present (out of 39,328,820 eligible).
- Dafni Bika, Ph.D. and Inese Lowenstein were elected as Class I Directors to serve until the 2028 Annual Meeting.
- Stockholders ratified PricewaterhouseCoopers LLP (PwC) as independent auditors for the fiscal year ending December 31, 2025.
Rapid Micro Biosystems, Inc. filed an 8-K to announce its financial results for the first quarter ended March 31, 2025.
📋 Key Facts
- Reporting period: First Quarter ended March 31, 2025
- Filing date: May 9, 2025
- The filing includes a press release (Exhibit 99.1) containing the quarterly financial results.
Rapid Micro Biosystems, Inc. has updated its corporate presentation to be used in meetings with investors and analysts.
📋 Key Facts
- The company updated its corporate presentation on March 4, 2025.
- The updated presentation is available via the Investor Relations section of the company's website.
- The filing includes Exhibit 99.1 containing the new presentation.
Rapid Micro Biosystems, Inc. filed an 8-K to announce its financial results for the fourth quarter and fiscal year ended December 31, 2024.
📋 Key Facts
- Report date: February 28, 2025
- Reporting period: Fourth quarter and fiscal year ended December 31, 2024
- The filing includes a press release as Exhibit 99.1 containing the financial results.
Rapid Micro Biosystems entered into a five-year global, co-exclusive Distribution and Collaboration Agreement with MilliporeSigma (a subsidiary of Merck KGaA). The agreement grants MilliporeSigma rights to sell Growth Direct systems and consumables across various industrial sectors globally.
🚩 Red Flags
- Co-exclusive nature of the agreement may limit the company's ability to appoint other major distributors for the covered products while MilliporeSigma's purchase commitments are active.
📋 Key Facts
- Agreement date: February 21, 2025; Filing date: February 27, 2025.
- Counterparty: Millipore S.A.S. (MilliporeSigma), a subsidiary of Merck KGaA.
- Scope: Global, co-exclusive rights for Growth Direct systems and consumables in pharmaceutical, medical device, personal care, cosmetics, and food/beverage sectors.
- Term: Initial term is five years.
- Commitments: MilliporeSigma committed to a minimum purchase of Growth Direct systems over the first two years.
- Future Collaboration: Parties intend to negotiate a supply agreement within six months to explore cost-saving measures in the supply chain and a services agreement within one year.
Rapid Micro Biosystems, Inc. has updated its corporate presentation to be used in meetings with investors and analysts. This is a routine disclosure under Item 7.01 (Regulation FD Disclosure).
📋 Key Facts
- The company updated its corporate presentation on January 16, 2025.
- The update is intended for use in meetings with investors, analysts, and other stakeholders.
- The presentation is available via the company's Investor Relations website.
Rapid Micro Biosystems, Inc. issued an 8-K to announce preliminary unaudited revenue results and business highlights for the fourth quarter and full year ended December 31, 2024.
📋 Key Facts
- Report date: January 14, 2025
- Reporting period: Q4 and Full Year ended December 31, 2024
- Content: Preliminary unaudited revenue results and business highlights
- Status: Information is non-filed under Section 18 of the Exchange Act
Rapid Micro Biosystems, Inc. has regained compliance with the Nasdaq minimum bid price requirement after its stock price met or exceeded $1.00 for ten consecutive business days. This resolves the delisting risk that had been pending since February 2024.
🚩 Red Flags
- Historical delisting risk (though now resolved)
📋 Key Facts
- The Company received a notification on November 11, 2024, confirming it has regained compliance with Nasdaq Listing Rule 5550(a)(2).
- Compliance was achieved after the closing bid price remained at or above $1.00 for ten consecutive business days.
- The Company had previously been transferred from the Nasdaq Global Select Market to the Nasdaq Capital Market on August 5, 2024, due to non-compliance.
- The compliance deadline was originally set for January 27, 2025.
Rapid Micro Biosystems, Inc. announced its Q3 2024 financial results and the resignation of a long-standing board member. The company also provided forward-looking guidance regarding revenue and product placements.
🚩 Red Flags
- Forward-looking statements highlight risks related to achieving positive cash flow without additional financing and significant losses since inception.
📋 Key Facts
- David Hirsch, M.D., Ph.D., resigned from the Board of Directors and all committees effective November 1, 2024.
- Dr. Hirsch served as a Class I director and member of the compensation committee since June 2013.
- The company issued unaudited financial results for the third quarter ended September 30, 2024.
- Resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
Rapid Micro Biosystems is transferring its listing from the Nasdaq Global Select Market to the Nasdaq Capital Market effective August 5, 2024, due to failure to regain compliance with the $1.00 minimum bid price requirement. The company has secured a second compliance period through January 27, 2025, and may implement a reverse stock split to maintain its listing.
🚩 Red Flags
- Delisting/Transfer: Downgrade from Global Select Market to Capital Market due to low stock price.
- Potential Reverse Stock Split: Explicitly identified as a potential remedial action for the bid price deficiency.
- Compliance Risk: Failure to meet the $1.00 minimum bid requirement during the initial period.
📋 Key Facts
- The initial compliance period for the Bid Price Requirement expired on July 31, 2024.
- Effective August 5, 2024, common stock will transfer from Nasdaq Global Select Market to Nasdaq Capital Market.
- A second compliance period has been granted, ending January 27, 2025.
- The company explicitly mentioned the potential implementation of a reverse stock split to regain compliance.
- Company announced unaudited Q2 2024 financial results via press release on August 2, 2024.
Rapid Micro Biosystems, Inc. reported the results of its annual meeting of stockholders held on May 23, 2024. The meeting included the election of three Class III Directors and the ratification of PricewaterhouseCoopers LLP as independent auditors.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Annual Meeting held on May 23, 2024.
- Elected Kirk D. Malloy, Ph.D., Melinda Litherland, and Robert Spignesi as Class III Directors to serve until the 2027 Annual Meeting.
- Ratified PricewaterhouseCoopers LLP (PwC) as independent registered public accounting firm for fiscal year ending Dec 31, 2024.
- Approved a Certificate of Amendment to the Restated Certificate of Incorporation to allow for officer exculpation under Delaware law.
- Total shares eligible to vote: 37,483,559; Total shares present/proxied: 35,030,255.
Rapid Micro Biosystems, Inc. filed an 8-K to announce its unaudited financial results for the first quarter ended March 31, 2024.
🚩 Red Flags
- Forward-looking statements highlight significant losses since inception and risks regarding cash runway/financial position.
📋 Key Facts
- Report date: May 3, 2024
- Reporting period: Q1 ended March 31, 2024
- The filing includes unaudited financial results via a press release (Exhibit 99.1)
- Company is an emerging growth company
Rapid Micro Biosystems, Inc. filed an 8-K to announce its financial results for the fourth quarter and full fiscal year ended December 31, 2023.
🚩 Red Flags
- The company notes 'significant losses since inception' in its cautionary statement, which is a standard risk disclosure but worth monitoring for micro-cap liquidity.
📋 Key Facts
- The filing is a standard earnings release under Item 2.02.
- Report date: March 1, 2024.
- Covers Q4 and full fiscal year 2023 results.
- Includes forward-looking statements regarding 2024 revenue guidance and product launches.
Rapid Micro Biosystems, Inc. received a notification from Nasdaq stating it is in non-compliance with the minimum bid price requirement after its stock closed below $1.00 for 30 consecutive business days. The company has until July 31, 2024, to regain compliance or face potential delisting.
🚩 Red Flags
- Failure to meet Nasdaq minimum bid price requirement ($1.00).
- Risk of delisting from the Nasdaq Global Select Market.
- Significant losses since inception mentioned in cautionary statement.
📋 Key Facts
- Nasdaq notification received on February 2, 2024.
- Non-compliance period: December 18, 2023, through February 1, 2024 (30 consecutive business days below $1.00).
- Compliance deadline: July 31, 2024.
- Requirement to regain compliance: Closing bid price must be at least $1.00 for 10-20 consecutive business days.
- Potential secondary option: Transfer listing to Nasdaq Capital Market if the company meets market value requirements.
Rapid Micro Biosystems announced preliminary unaudited revenue results for Q4 and FY2023, showing significant year-over-year growth. The company also provided updates on its product pipeline and reported a strong cash position with runway extending into 2026.
📋 Key Facts
- Q4 2023 preliminary revenue expected: $6.2M - $6.4M (approx. 45% YoY growth).
- Full Year 2023 total revenue expected: $22.4M - $22.6M (over 30% YoY growth).
- Cash, cash equivalents, and investments totaled approximately $95 million as of Dec 31, 2023.
- Cash runway is expected to last at least into the second half of 2026.
- Growth Direct Rapid Sterility application commercial launch expected by mid-year 2024.
- Growth Direct systems are currently placed with 100% of commercially approved CAR-T therapy manufacturers.